Ebglyss FDA approval intensifies competition in atopic dermatitis market: GlobalData
Eli Lilly’s Ebglyss enters the US market, poised to challenge established therapies like Dupixent and Adbry/Adtralza in the atopic…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
lebrikizumab
FDA rejection to delay Lebrikizumab chances to enter atopic dermatitis market: GlobalData
GlobalData currently expects Lilly to resubmit lebrikizumab’s BLA in Q4 2023